Living Competitors

Pink Sheets . USA . 
Stock . Living Cell Technologies
LVCLF Stock  USD 0.01  0.00  0.00%   
Living Cell Technologies competes with Hookipa Pharma, Devonian Health, ImmunoCellular Therapeutics, and Propanc Biopharma,; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Living Cell competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Living Cell to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Living Cell Correlation with its peers.

Living Cell vs Propanc Biopharma, Correlation

Pay attention - limited upside

The correlation between Living Cell Technologies and PPCB is -0.75 (i.e., Pay attention - limited upside) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Living Cell Technologies and PPCB in the same portfolio, assuming nothing else is changed.

Moving together with Living Pink Sheet

  0.63NONOF Novo Nordisk ASPairCorr

Moving against Living Pink Sheet

  0.82ARGX argenx NV ADRPairCorr
  0.68ALNY Alnylam PharmaceuticalsPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.000.017.72
Details
Intrinsic
Valuation
LowRealHigh
0.000.017.72
Details

Living Cell Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Living Cell and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Living and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Living Cell Technologies does not affect the price movement of the other competitor.

High positive correlations

VPHIF
+ 0.52
NYMXF
HMTXF
+ 0.44
HOOK
NYMXF
+ 0.4
OXBOF
IMUC
+ 0.38
OXBOF
VPHIF
+ 0.37
OXBOF
PPCB
+ 0.37
NYMXF
  

High negative correlations

PPCB
- 0.9
HOOK
VPHIF
- 0.56
LIANY
LIANY
- 0.42
NYMXF
PPCB
- 0.4
HMTXF
LIANY
- 0.34
OXBOF
NYMXF
- 0.23
HOOK

Risk-Adjusted Indicators

There is a big difference between Living Pink Sheet performing well and Living Cell Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Living Cell's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
HOOK  1.29  0.31  0.09 (0.48) 1.22 
(1.99)
 3.45 
(2.25)
 10.16 
OXBOF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
DVHGF  62.64  23.31  0.00  0.36  0.00 
 0.00 
 0.00 
 0.00 
 1,098 
IMUC  17.71  4.58  0.16  0.78  15.07 
(40.46)
 50.00 
(35.45)
 223.80 
NYMXF  10.10  0.20  0.00 (0.02) 11.78 
(14.54)
 36.54 
(23.15)
 82.03 
HMTXF  2.76  0.19  0.02  0.28  3.91 
(6.49)
 9.87 
(8.76)
 41.09 
SRBCF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
LIANY  4.46  0.82  0.07  1.03  5.24 
(12.03)
 12.12 
(7.14)
 60.61 
VPHIF  2.12 (0.72) 0.00  0.21  0.00 
 0.00 
 0.00 
 0.00 
 66.67 
PPCB  5.41 (1.59) 0.00  1.91  0.00 
 0.00 
 7.89 
(14.89)
 58.21 

Living Cell Competitive Analysis

The better you understand Living Cell competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Living Cell's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Living Cell's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
LVCLF HOOK OXBOF DVHGF IMUC NYMXF HMTXF SRBCF LIANY VPHIF
 0.00 
 0.01 
Living
 3.77 
 1.02 
Hookipa
 0.00 
 0 
Oxford
 0.00 
 4.27 
Devonian
 28.57 
 0.18 
ImmunoCellular
 20.24 
 0.05 
Nymox
 3.12 
 0.07 
Hemostemix
 0.00 
 0.01 
Sirona
 2.15 
 0.09 
LianBio
 0.00 
 0.0001 
Valeo
Market Volatility
(90 Days Market Risk)
Out of control
Very risky
Out of control
Out of control
Out of control
Unknown risk
Out of control
Risky
Out of control
Out of control
Market Performance
(90 Days Performance)
Fair
Good
Weak
Good
Good
Weakest
Soft
Weakest
Fair
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Small
Fair
Small
Moderate
Unknown
Strong
Low
Unknown
High
Current Valuation
(Equity Enterprise Value)
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Strong Buy
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
17.84
5.48
2.98
9.07
1.51
N/A
0.29
2.6
N/A
2.88
Net Asset
4.27 M
82.55 M
11.34 M
21.59 M
N/A
N/A
563.05 K
1.29 M
N/A
58.27 M
Profit Margin
N/A
N/A
N/A
-1.67
N/A
N/A
N/A
N/A
N/A
-0.93
EBITDA
(2.38 M)
(40.85 M)
(6.16 M)
(1.65 M)
(6.07 M)
N/A
(6.53 M)
(2.3 M)
N/A
(19.04 M)
Operating Margin
-428.7
-8.85
-55.85
-1.48
N/A
N/A
N/A
-4.92
N/A
-0.61
Current Valuation
12.53 M
(20.98 M)
37.52 M
42.9 M
(1.69 M)
N/A
9.27 M
24.5 M
N/A
57.28 M
Price To Book
6.96
0.44
0.19
2.75
0.35
N/A
39.23
36.93
N/A
66.75
Retained Earnings
(67 M)
(412.76 M)
N/A
N/A
(74.14 M)
N/A
(19.5 M)
(12.03 M)
N/A
N/A
Current Asset
6 M
26.61 M
N/A
N/A
24.56 M
N/A
175 K
1.49 M
N/A
N/A
Beta
0.27
0.89
1.21
1.22
1.03
N/A
0.54
-0.36
N/A
2.47
Number Of Employees
15
82
9
3
3
N/A
6
12
N/A
115
Shares Outstanding
1.29 B
9.93 M
146.71 M
134.69 M
4.19 M
N/A
75.74 M
251.73 M
N/A
82.19 M
Cash Flow From Operations
(2.04 M)
(76.98 M)
(5.18 M)
(2.87 M)
(2.31 M)
N/A
(3.48 M)
(2.16 M)
N/A
(28.5 M)
Total Debt
228.44 K
875 K
6.46 M
4.26 M
2.78 M
N/A
1.48 M
468.77 K
N/A
59.53 M
Return On Equity
-0.72
-1.06
-1.45
-0.33
-23.12
N/A
N/A
-35.56
N/A
-16.0
Z Score
5.4
N/A
3.0
4.8
-2.8
N/A
-81.5
10.5
N/A
N/A
Return On Asset
-0.31
-0.45
-0.4
-0.12
-4.4
N/A
-2.49
-1.35
N/A
-0.26
Book Value Per Share
0.003
2.71
0.026
0.12
-0.033
N/A
-0.052
0.004
N/A
-0.22
Number Of Shares Shorted
N/A
35.8 K
N/A
N/A
165.95 K
N/A
N/A
N/A
N/A
N/A
Current Liabilities
1000 K
25.01 M
N/A
N/A
2.27 M
N/A
1.49 M
801 K
N/A
N/A
Total Asset
4.27 M
82.55 M
11.34 M
21.59 M
30.08 M
N/A
563.05 K
1.29 M
N/A
58.27 M
Debt To Equity
0.1
0.052
0.99
0.31
0.39
N/A
N/A
0.6
N/A
N/A
Short Ratio
N/A
0.57
N/A
N/A
4.13
N/A
N/A
N/A
N/A
N/A
Target Price
N/A
2.0
N/A
N/A
5.0
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
12.16
52.68
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Market Capitalization
9.81 M
13.07 M
37.41 M
36.79 M
2.21 M
N/A
12.96 M
20.74 M
N/A
35.68 M
Price To Earning
-31.67
12.06
N/A
N/A
0.02
N/A
N/A
-7.33
N/A
N/A
Price To Earnings To Growth
N/A
-0.19
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Price To Sales
5586.88
1.4
198.91
19.73
N/A
N/A
N/A
36.46
N/A
2.14
Net Income
(1.96 M)
(43.5 M)
(6.71 M)
(3.45 M)
(5.15 M)
N/A
(6.29 M)
(2.31 M)
N/A
(25.75 M)
Earnings Per Share
-0.002
-4.83
-0.088
N/A
28.91
N/A
-0.094
-0.012
N/A
-0.21
Shares Owned By Insiders
33.99
0.12
30.93
7.81
94.96
N/A
12.4
10.43
N/A
47.72
Revenue
3.4 K
43.95 M
154 K
2.31 M
N/A
N/A
N/A
268.02 K
N/A
27.75 M
Working Capital
5 M
56.01 M
N/A
N/A
22.29 M
N/A
(1.32 M)
692 K
N/A
N/A
Cash And Equivalents
4.24 M
117.92 M
4.59 M
9.49 M
933.15 K
N/A
649.32 K
1.13 M
N/A
27.72 M
Cash Per Share
N/A
2.16
0.05
0.07
0.01
N/A
0.01
N/A
N/A
0.34
Gross Profit
3.4 K
(50.47 M)
116 K
561.01 K
N/A
N/A
N/A
199.25 K
N/A
8.52 M
Day Typical Price
0.0079
1.02
0.002
4.27
0.18
0.0466
0.0662
0.0051
0.091
1.0E-4
Accumulation Distribution
N/A
0.0097
N/A
N/A
N/A
4980.75
N/A
N/A
N/A
N/A
Market Facilitation Index
N/A
0.01
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Daily Balance Of Power
0.0
(4.00)
0.0
0.0
9.2 T
0.8485
9.2 T
0.0
0
0.0
Period Momentum Indicator
N/A
(0.04)
N/A
N/A
0.04
0.0084
0.002
N/A
(0)
N/A
Rate Of Daily Change
1.0
0.96
1.0
1.0
1.29
1.2
1.03
1.0
0.98
1.0
Day Median Price
0.0079
1.02
0.002
4.27
0.18
0.045
0.0662
0.0051
0.091
1.0E-4
Price Action Indicator
N/A
(0.03)
N/A
N/A
0.02
0.0092
0.001
N/A
(0)
N/A
Coefficient Of Variation
N/A
652.27
N/A
617.36
698.64
27924.43
1992.16
N/A
981.28
(787.40)
Mean Deviation
N/A
1.29
N/A
62.64
17.71
10.1
2.76
N/A
4.46
2.12
Jensen Alpha
N/A
0.3063
N/A
23.31
4.58
0.1984
0.1942
N/A
0.8187
(0.72)
Total Risk Alpha
N/A
0.1096
N/A
13.43
1.97
(1.30)
(0.21)
N/A
0.119
(1.82)
Sortino Ratio
N/A
0.0939
N/A
N/A
0.163
(0)
0.0219
N/A
0.07
N/A
Downside Variance
N/A
4.37
N/A
N/A
929.3
224.27
74.77
N/A
133.37
N/A
Standard Deviation
N/A
1.81
N/A
179.57
35.28
15.49
5.38
N/A
8.72
8.47
Kurtosis
N/A
1.72
N/A
27.78
13.61
2.46
6.65
N/A
8.87
62.0
Potential Upside
N/A
3.45
N/A
N/A
50.0
36.54
9.87
N/A
12.12
N/A
Treynor Ratio
N/A
(0.48)
N/A
0.3568
0.7764
(0.02)
0.2787
N/A
1.03
0.2084
Maximum Drawdown
N/A
10.16
N/A
1098.33
223.8
82.03
41.09
N/A
60.61
66.67
Variance
N/A
3.26
N/A
32244.06
1244.39
239.92
28.98
N/A
76.06
71.68
Market Risk Adjusted Performance
N/A
(0.47)
N/A
0.3668
0.7864
(0.01)
0.2887
N/A
1.04
0.2184
Risk Adjusted Performance
N/A
0.13
N/A
0.1415
0.126
0.0124
0.0493
N/A
0.0918
(0.09)
Skewness
N/A
0.5709
N/A
5.34
3.21
1.1
0.7183
N/A
1.52
(7.87)
Semi Deviation
N/A
1.22
N/A
N/A
15.07
11.78
3.91
N/A
5.24
N/A
Information Ratio
N/A
0.1086
N/A
0.1615
0.1408
(0)
0.0352
N/A
0.0926
(0.14)
Value At Risk
N/A
(2.25)
N/A
N/A
(35.45)
(23.15)
(8.76)
N/A
(7.14)
N/A
Expected Short fall
N/A
(1.99)
N/A
N/A
(40.46)
(14.54)
(6.49)
N/A
(12.03)
N/A
Downside Deviation
N/A
2.09
N/A
N/A
30.48
14.98
8.65
N/A
11.55
N/A
Semi Variance
N/A
1.49
N/A
N/A
227.16
138.78
15.3
N/A
27.47
N/A

Living Cell Competition Performance Charts

Five steps to successful analysis of Living Cell Competition

Living Cell's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Living Cell Technologies in relation to its competition. Living Cell's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Living Cell in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Living Cell's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Living Cell Technologies, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Living Cell position

In addition to having Living Cell in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Warren Buffett Holdings Thematic Idea Now

Warren Buffett Holdings
Warren Buffett Holdings Theme
A long-term portfolio of publicly-traded stocks on US exchanges that are owned by Warren Buffett's holding company Berkshire Hathaway. The Warren Buffett Holdings theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Warren Buffett Holdings Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Living Pink Sheet

Living Cell financial ratios help investors to determine whether Living Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Living with respect to the benefits of owning Living Cell security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY